These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 33226664)

  • 21. Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.
    Yang Y; Zhang X
    Methods Mol Biol; 2022; 2486():57-69. PubMed ID: 35437718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
    Tse S; Dowty ME; Menon S; Gupta P; Krishnaswami S
    J Clin Pharmacol; 2020 Dec; 60(12):1617-1628. PubMed ID: 32592424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.
    Cattaneo D; Pasina L; Maggioni AP; Giacomelli A; Oreni L; Covizzi A; Bradanini L; Schiuma M; Antinori S; Ridolfo A; Gervasoni C
    Drugs Aging; 2020 Dec; 37(12):925-933. PubMed ID: 33150470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
    Cheong EJY; Teo DWX; Chua DXY; Chan ECY
    Drug Metab Dispos; 2019 Nov; 47(11):1291-1306. PubMed ID: 31506301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.
    Munir A; Azam S; Fazal S; Bhatti AI
    J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction.
    Prieto Garcia L; Lundahl A; Ahlström C; Vildhede A; Lennernäs H; Sjögren E
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1194-1209. PubMed ID: 35722750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.
    Rowland Yeo K; Zhang M; Pan X; Ban Ke A; Jones HM; Wesche D; Almond LM
    Clin Pharmacol Ther; 2020 Nov; 108(5):976-984. PubMed ID: 32531808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
    Lin L; Wright MR; Hop CECA; Wong H
    Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.
    Mayumi K; Ohnishi S; Hasegawa H
    J Pharm Sci; 2019 Aug; 108(8):2718-2727. PubMed ID: 30876861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
    Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
    Xu R; Ge W; Jiang Q
    Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.